Ambit Biosciences

Is Ambit Biosciences Getting Enough in Its Buyout?
Yahoo/24-7 Wall St
Mon, 09/29/14 - 01:53 pm
M&A
Ambit Biosciences
Daiichi Sankyo
Daiichi Sankyo to Buy Ambit to Boost Cancer Drug Pipeline
Bloomberg
Mon, 09/29/14 - 07:55 am
Daiichi Sankyo
Ambit Biosciences
M&A
Ambit's Oncology Drug in Phase III
Yahoo/Zacks.com
Wed, 04/9/14 - 09:34 pm
Ambit Biosciences
quizartinib
acute myeloid leukemia
Biotech Stock Bubble Debate in 14 Charts
TheStreet.com
Wed, 10/23/13 - 08:32 am
biotech
Bluebird Bio
Celgene
Celldex
Onconova
Aegerion
Receptos
Immunomedics
Alcobra
Gilead
Biogen Idec
Ambit Biosciences
US FDA okays Ambit Biosciences & Teva's IND for CEP-32496, a novel BRAF inhibitor
Pharmabiz
Sat, 05/19/12 - 12:26 pm
Ambit Biosciences
Teva Pharmaceuticals
CEP-32496
cancer
melanoma
lung cancer
thyroid cancer
colon cancer
ovarian cancer